Monday, September 14, 2026

Alteogen Signs Subcutaneous Injection Development Deal With Novartis Worth Up to $3.22 Billion

Alteogen has signed an option and licensing agreement with Novartis to develop and commercialize subcutaneous formulations based on its ALT-B4 technology, with potential payments of up to $3.22 billion plus royalties.

How the Bank of Korea is Tackling AI Cyber Threats with Palo Alto Networks: A Deep Dive

The Bank of Korea adopts Palo Alto Networks' cybersecurity solutions to enhance security against AI-driven threats like Mythos.

51st Air Control Squadron Honored for Excellence in Combat Power Development

The 51st Air Control Squadron received the Combat Power Development award for enhancing air surveillance and response capabilities.

Tag: domestic visitors

No posts to display

Top News

- Our Sponsors Ad -

Follow us